AscellaHealth Releases Q2 2024 Specialty & Rare Pipeline Digest™: Increased Approvals Signal Growing Demand and Utilization of Specialty Pharmaceuticals

BERWYN, Pa.--(BUSINESS WIRE)--AscellaHealth, a global partner that delivers proven end-to-end solutions to both life sciences and healthcare companies to enhance the quality of life for patients with complex, chronic conditions, today released its latest Specialty & Rare Pipeline Digest™, the industry’s most comprehensive quarterly resource of new, pending and upcoming specialty and rare disease drug launches, cell and gene therapies (CGT), biosimilars and generics. This complimentary digital publication provides timely product updates to support the specialty drug market needs of stakeholders and decision-makers

To read more, click here